Tumor cells escape immunosurveillance by hampering LFA-1
During tumor immunosurveillance, leukocytes play a crucial role in the cellular defense system, working collaboratively with other immune components to recognize and eliminate aberrant cells. Integral to this process is the integrin Lymphocyte Function-Associated Antigen 1 (LFA-1). LFA-1 facilitates...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1519841/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591664526393344 |
|---|---|
| author | Shishir Upadhyay Lewis Murugu Lena Svensson Lena Svensson |
| author_facet | Shishir Upadhyay Lewis Murugu Lena Svensson Lena Svensson |
| author_sort | Shishir Upadhyay |
| collection | DOAJ |
| description | During tumor immunosurveillance, leukocytes play a crucial role in the cellular defense system, working collaboratively with other immune components to recognize and eliminate aberrant cells. Integral to this process is the integrin Lymphocyte Function-Associated Antigen 1 (LFA-1). LFA-1 facilitates adhesion during leukocyte migration and helps establish stable cell-to-cell contacts between leukocytes and their targets. Additionally, as a receptor, LFA-1 signaling activates leukocytes, promoting their differentiation and effector functions against cancer. However, tumors can develop mechanisms to evade immune clearance by disrupting LFA-1 functions or hijacking its pathways. In this review, we first detail how leukocytes utilize LFA-1 during immunosurveillance and then explore how tumors counteract this process in the tumor microenvironment (TME) by either altering LFA-1 functions or exploiting it to drive tumorigenesis. Moreover, we discuss therapeutic strategies targeting LFA-1, including inhibitors tested in laboratory studies and animal models, highlighting their potential as anticancer interventions and the need for further research to evaluate their clinical utility. |
| format | Article |
| id | doaj-art-df9d417f7b0846d5af52a989f4bffd85 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-df9d417f7b0846d5af52a989f4bffd852025-01-22T07:14:00ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15198411519841Tumor cells escape immunosurveillance by hampering LFA-1Shishir Upadhyay0Lewis Murugu1Lena Svensson2Lena Svensson3Department of Molecular Biology, Umeå University, Umeå, SwedenDepartment of Molecular Biology, Umeå University, Umeå, SwedenDepartment of Molecular Biology, Umeå University, Umeå, SwedenUmeå Centre for Microbial Research, Umeå University, Umeå, SwedenDuring tumor immunosurveillance, leukocytes play a crucial role in the cellular defense system, working collaboratively with other immune components to recognize and eliminate aberrant cells. Integral to this process is the integrin Lymphocyte Function-Associated Antigen 1 (LFA-1). LFA-1 facilitates adhesion during leukocyte migration and helps establish stable cell-to-cell contacts between leukocytes and their targets. Additionally, as a receptor, LFA-1 signaling activates leukocytes, promoting their differentiation and effector functions against cancer. However, tumors can develop mechanisms to evade immune clearance by disrupting LFA-1 functions or hijacking its pathways. In this review, we first detail how leukocytes utilize LFA-1 during immunosurveillance and then explore how tumors counteract this process in the tumor microenvironment (TME) by either altering LFA-1 functions or exploiting it to drive tumorigenesis. Moreover, we discuss therapeutic strategies targeting LFA-1, including inhibitors tested in laboratory studies and animal models, highlighting their potential as anticancer interventions and the need for further research to evaluate their clinical utility.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1519841/fullLFA-1leukocytescancerTMEimmunosurveillanceimmune escape |
| spellingShingle | Shishir Upadhyay Lewis Murugu Lena Svensson Lena Svensson Tumor cells escape immunosurveillance by hampering LFA-1 Frontiers in Immunology LFA-1 leukocytes cancer TME immunosurveillance immune escape |
| title | Tumor cells escape immunosurveillance by hampering LFA-1 |
| title_full | Tumor cells escape immunosurveillance by hampering LFA-1 |
| title_fullStr | Tumor cells escape immunosurveillance by hampering LFA-1 |
| title_full_unstemmed | Tumor cells escape immunosurveillance by hampering LFA-1 |
| title_short | Tumor cells escape immunosurveillance by hampering LFA-1 |
| title_sort | tumor cells escape immunosurveillance by hampering lfa 1 |
| topic | LFA-1 leukocytes cancer TME immunosurveillance immune escape |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1519841/full |
| work_keys_str_mv | AT shishirupadhyay tumorcellsescapeimmunosurveillancebyhamperinglfa1 AT lewismurugu tumorcellsescapeimmunosurveillancebyhamperinglfa1 AT lenasvensson tumorcellsescapeimmunosurveillancebyhamperinglfa1 AT lenasvensson tumorcellsescapeimmunosurveillancebyhamperinglfa1 |